KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $251.5 million.

  • Jazz Pharmaceuticals' Net Income towards Common Stockholders rose 1677.3% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$275.8 million, marking a year-over-year decrease of 15926.84%. This contributed to the annual value of $561.8 million for FY2024, which is 3444.83% up from last year.
  • Jazz Pharmaceuticals' Net Income towards Common Stockholders amounted to $251.5 million in Q3 2025, which was up 1677.3% from -$718.4 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $251.5 million during Q3 2025, with a 5-year trough of -$718.4 million in Q2 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $53.8 million (2022), whereas its average is -$1.7 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Net Income towards Common Stockholders plummeted by 64182.59% in 2022 and then surged by 111653.14% in 2023.
  • Quarter analysis of 5 years shows Jazz Pharmaceuticals' Net Income towards Common Stockholders stood at -$32.3 million in 2021, then tumbled by 641.83% to -$240.0 million in 2022, then soared by 139.43% to $94.6 million in 2023, then surged by 102.01% to $191.1 million in 2024, then soared by 31.56% to $251.5 million in 2025.
  • Its last three reported values are $251.5 million in Q3 2025, -$718.4 million for Q2 2025, and $191.1 million during Q4 2024.